Evidence map›Paper›PMID 35842521›Full record

ArticleBreast cancer research and treatment2022

Primary care physician referral practices regarding BRCA1/2 genetic counseling in a major health system.

Debra T Linfield, Michael B Rothberg, Elizabeth R Pfoh, Ryan Noss, Lydia Cassard, Joseph C Powers, Laura Lipold, Kathryn A Martinez

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Debra T LinfieldCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
Michael B RothbergCleveland Clinic Center for Value-Based Care Research, 9500 Euclid Avenue, Desk G10, Cleveland, OH, 44195, USA.
Elizabeth R PfohCleveland Clinic Center for Value-Based Care Research, 9500 Euclid Avenue, Desk G10, Cleveland, OH, 44195, USA.
Ryan NossCenter for Personalized Genetic Healthcare, Cleveland Clinic Foundation, Cleveland, OH, USA.
Lydia CassardCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
Joseph C PowersCleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
Laura LipoldDepartment of Family Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.
Kathryn A MartinezCleveland Clinic Center for Value-Based Care Research, 9500 Euclid Avenue, Desk G10, Cleveland, OH, 44195, USA. martink12@ccf.org.ORCID http://orcid.org/0000-0001-9177-480X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe United States Preventive Services Task Force recommends primary care physicians refer patients at high risk for BRCA1/2 mutations to genetic testing when appropriate. The objective of our study was to describe referrals for BRCA1/2 testing in a large integrated health system and to assess factors associated with referral.

methodsThis retrospective cohort study includes female patients between 18 and 50 years who had a primary care visit in the Cleveland Clinic Health System between 2010 and 2019. We used multivariable logistic regression to estimate differences in the odds of a woman being referred for BRCA1/2 testing by patient factors and referring physician specialty. We also assessed variation in referrals by physicians.

resultsAmong 279,568 women, 5% were high risk. Of those, 22% were referred for testing. Black patients were significantly less likely to be referred than white patients (aOR 0.87; 95% CI 0.77, 0.98) and Jewish patients were more likely to be referred than non-Jewish patients (aOR 2.13; 95% CI 1.68, 2.70). Patients primarily managed by OB/GYN were significantly more likely to be referred than those cared for via Internal/Family Medicine (aOR 1.45; 95% CI 1.30, 1.61). Less than a quarter of primary care physicians ever referred a patient for testing.

conclusionThe majority of primary care patients at high risk for a BRCA1/2 mutation were not referred for testing, and over a decade, most physicians never referred a single patient. Internal/Family Medicine physicians, in particular, need support in identifying and referring women who could benefit from testing.

Indexed as

Breast NeoplasmsPhysicians, Primary CareBRCA1 ProteinBRCA2 ProteinFemaleGenes, BRCA1Genes, BRCA2Genetic CounselingGenetic Predisposition to DiseaseGenetic TestingHumansReferral and ConsultationRetrospective StudiesUnited StatesBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA1BRCA2Breast cancerGenetic counselingGenetic testing

Identifiers

PMID35842521

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.